Share this article
Share this article
NEW YORK, April 13, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ( Provention or the Company ) (NASDAQ: PRVB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Provention and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 8, 2021, Provention issued a press release announc[ing] that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company s Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace
Share this article
Share this article
RED BANK, N.J., April 8, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company s Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The FDA stated in the correspondence that the notification does not reflect a final decision on the information under review.
Form 6-K ADC Therapeutics SA For: Apr 06 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Search jobs Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
Senior pharmaceutical executive with deep oncology experience in Asia formerly of Takeda, MSD, Bayer and Pfizer
BOSTON, SHANGHAI & LAUSANNE, Switzerland (BUSINESS WIRE) Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointment of Eric Koo, BSc, MBA, as Chief Executive Officer. Mr. Koo brings more than 25 years of pharmaceutical industry and business management experience to Overland ADCT BioPharma with a proven track record of executing successful drug approvals and launches across Asia.
“Overland ADCT BioPharma has a tremendous opportunity to bridge the clinical gap between the U.S., Europe and Asia through the expanded reach of innovative cancer medicines like antibody drug conjugates,” said Eric Koo, BSc, MBA. “It is an honor to assume the role of Chief Executive Officer and I l